TY - JOUR
T1 - Current practices in pediatric hospital-acquired thromboembolism
T2 - Survey of the Children's Hospital Acquired Thrombosis (CHAT) Consortium
AU - for the CHAT Consortium Investigators
AU - the VTE Risk Factors and Thromboprophylaxis Working Group of the Pediatric and Neonatal Thrombosis and Hemostasis Subcommittee of the ISTH SSC
AU - Abrams, Christina M.
AU - Jaffray, Julie
AU - Stillings, Amy
AU - Branchford, Brian R
AU - Young, Guy
AU - Goldenberg, Neil A.
AU - Abajas, Yasmina L.
AU - Fargo, John
AU - Crary, Shelly
AU - Kumar, Riten
AU - Woods, Gary
AU - Narang, Shalu
AU - Cooper, James
AU - Silvey, Mike
AU - Garland, Kate
AU - Mahajerin, Arash
AU - Luchtman-Jones, Lori
AU - Torres, Marcela
AU - Wright, Jordan
AU - Pahl, Kristy
AU - Armstrong, Katherine
AU - Braunreiter, Chi
AU - Bakeer, Nihal
AU - Sochet, Anthony
AU - Hogan, Marie
AU - Gupta, Shveta
AU - Knoll, Christine
AU - Hege, Kerry
AU - Schaefer, Beverly
AU - Panigrahi, Arun
AU - Thornburg, Courtney
AU - Shimano, Kristin
AU - Ahuja, Sanjay
AU - Weyand, Angela
AU - Boucher, Alexander
AU - Abajas, Yasmina
AU - Subbaswamy, Anjali
AU - Khan, Osman
AU - Druzgal, Colleen
AU - Maida, Deanna
AU - Wheeler, Allison
AU - Malec, Lynn
AU - Branchford, Brian
AU - Kucine, Nicole Elena
AU - Prozora, Stephanie
N1 - Publisher Copyright:
© 2022 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH).
PY - 2022/10
Y1 - 2022/10
N2 - Background: A rise in hospital-acquired venous thromboembolism (HA-VTE) in children has led to increased awareness regarding VTE prophylaxis and risk assessment. Despite this, no consensus exists regarding these practices in pediatrics. Objective: To describe common practices in VTE prophylaxis, VTE risk assessment models, and anticoagulation dosing strategies in pediatric hospitals that are members of the Children's Hospital Acquired Thrombosis (CHAT) Consortium. Methods: An electronic survey of 44 questions evaluating practices surrounding pediatric HA-VTE risk assessment and prevention was distributed between August 9, 2021, and August 30, 2021, to the primary investigators from the 32 institutions within the CHAT Consortium. Results: The survey response rate was 100% (n = 32). In total, 85% (n = 27) of the institutions assess HA-VTE, but only 63% (n = 20) have formal hospital guidelines. Within the institutions with formal guidelines, 100% (n = 20) include acute systemic inflammation or infection and presence of a central venous catheter (CVC) as risk factors for VTE. Pharmacologic prophylaxis is prescribed at 87% (28) of institutions, with enoxaparin being the most frequent (96%, n = 27). Variability in responses persisted regarding risk factors, risk assessment, thromboprophylaxis, dosing of prophylactic anticoagulation or anticoagulant drug monitoring. A majority of providers were comfortable providing thromboprophylaxis across all age groups. In addition, the global coronavirus disease 2019 increased the providers' use of prophylactic anticoagulation 78% (n = 25). Conclusion: Practices among institutions are variable in regard to use of HA-VTE prophylaxis, risk assessment, or guideline implementation, highlighting the need for further research and a validated risk assessment model through groups like the CHAT Consortium.
AB - Background: A rise in hospital-acquired venous thromboembolism (HA-VTE) in children has led to increased awareness regarding VTE prophylaxis and risk assessment. Despite this, no consensus exists regarding these practices in pediatrics. Objective: To describe common practices in VTE prophylaxis, VTE risk assessment models, and anticoagulation dosing strategies in pediatric hospitals that are members of the Children's Hospital Acquired Thrombosis (CHAT) Consortium. Methods: An electronic survey of 44 questions evaluating practices surrounding pediatric HA-VTE risk assessment and prevention was distributed between August 9, 2021, and August 30, 2021, to the primary investigators from the 32 institutions within the CHAT Consortium. Results: The survey response rate was 100% (n = 32). In total, 85% (n = 27) of the institutions assess HA-VTE, but only 63% (n = 20) have formal hospital guidelines. Within the institutions with formal guidelines, 100% (n = 20) include acute systemic inflammation or infection and presence of a central venous catheter (CVC) as risk factors for VTE. Pharmacologic prophylaxis is prescribed at 87% (28) of institutions, with enoxaparin being the most frequent (96%, n = 27). Variability in responses persisted regarding risk factors, risk assessment, thromboprophylaxis, dosing of prophylactic anticoagulation or anticoagulant drug monitoring. A majority of providers were comfortable providing thromboprophylaxis across all age groups. In addition, the global coronavirus disease 2019 increased the providers' use of prophylactic anticoagulation 78% (n = 25). Conclusion: Practices among institutions are variable in regard to use of HA-VTE prophylaxis, risk assessment, or guideline implementation, highlighting the need for further research and a validated risk assessment model through groups like the CHAT Consortium.
KW - anticoagulants
KW - hospital
KW - pediatric
KW - risk assessment
KW - risk factors
KW - venous thromboembolism
UR - http://www.scopus.com/inward/record.url?scp=85142112093&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85142112093&partnerID=8YFLogxK
U2 - 10.1002/rth2.12793
DO - 10.1002/rth2.12793
M3 - Article
C2 - 38024326
AN - SCOPUS:85142112093
SN - 2475-0379
VL - 6
JO - Research and Practice in Thrombosis and Haemostasis
JF - Research and Practice in Thrombosis and Haemostasis
IS - 7
M1 - e12793
ER -